⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 13, 2024

Figure S2 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations

Ursula Grazini Aleksandra Markovets Lucy Ireland Daniel O’Neill Benjamin Phillips Man Xu Matthias Pfeifer Tereza Vaclová Matthew J. Martin Ludovic Bigot Luc Friboulet Ryan J. Hartmaier Maria Emanuela Cuomo Simon T. Barry Paul D. Smith Nicolas Floc’h

View at Publisher

Ask AI

Bookmark

Share

Abstract

Figure S2: EGFRm NSCLC cells with PIK3CA GOF and PTEN LOF mutations show resistant to osimertinib and can be resensitized by co-treatment with the AKT inhibitor capivasertib (AZD5363).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Grazini et al. (2024) studied this question.

synapsesocial.com/papers/68e58a5ab6db6435875263f1 https://doi.org/10.1158/1078-0432.27013643

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S3 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024
2Figure S4 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024
3Figure S1 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024
4Data from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024
5Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024 · 27 citations

PIKing up and AKTing on resistance mutations in osimertinib-treated EGFR-mutated NSCLC2024
Table S1 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024
Table S1 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024